Treatment with semaglutide also resulted in better improvements in physical functioning and cardiometabolic risk determinants.[6] 2
There are also complaints about short appointments, scheduling issues, and some dissatisfaction with care
Practical Checklist Before Enrolling in Amble Before starting an intake with Amble or any GLP-1 telehealth platform, a woman should have the following information available: Current weight and height (BMI calculation) List of all medications, including oral contraceptives, metformin, or any insulin Recent labs within the past 12 months, including TSH, HbA1c, and a metabolic panel if available Documentation of any prior weight-loss pharmacotherapy, including which agent, dose, and reason for stopping Clarity on monthly budget including both platform fee and pharmacy cost Understanding that she will need to self-administer a subcutaneous injection weekly and store the pen correctly (refrigerated at 2-8 degrees Celsius) A woman who checks all these boxes, meets BMI criteria, has no contraindications, and can sustain the financial commitment for 12-24 months is a genuinely appropriate candidate for a GLP-1 program through a platform like Amble
(2018): [Epub ahead of print]
Avoid freeze-thaw cycles, which reduce bioactivity by 3040%
Related links CFTR2: Rights and permissions Springer Nature or its licensor (e.g
